AKTS

Aktis Oncology, Inc. AKTS

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$3.38M

Quarter to Jun 30

Net income

$-24.14M

Quarter to Jun 30

Free cash flow

$-21.85M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$1.10B total
MPM BioImpact LLC
$155.86M0.0%
EcoR1 Capital, LLC
$155.49M0.0%
Blue Owl Capital Holdings LP
$98.95M-2.9%
BlackRock, Inc.
$73.43M+7.9%
T. Rowe Price Investment Management, Inc.
$66.12M-3.4%
WELLINGTON MANAGEMENT GROUP LLP
$63.37M-15.1%
RTW INVESTMENTS, LP
$51.31M0.0%
RA CAPITAL MANAGEMENT, L.P.
$42.36M-12.6%
Jupiter Topco LLC
$42.36M--
BAKER BROS. ADVISORS LP
$32.11M0.0%
Octagon Capital Advisors LP
$30.97M0.0%
Merck & Co., Inc.
$30.71M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$26.33M-2.0%
PRICE T ROWE ASSOCIATES INC /MD/
$24.61M-51.2%
TCG Crossover Management, LLC
$22.45MNew
GEODE CAPITAL MANAGEMENT, LLC
$16.79M+5.9%
EVENTIDE ASSET MANAGEMENT, LLC
$16.34M0.0%
Avidity Partners Management LP
$15.61M+3.3%
STATE STREET CORP
$15.60M+13.0%
a16z Capital Management, L.L.C.
$13.38M0.0%
Alyeska Investment Group, L.P.
$9.35M0.0%
FMR LLC
$9.21M-26.1%
ArrowMark Colorado Holdings LLC
$7.92M-25.4%
NORTHERN TRUST CORP
$5.82M+20.8%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$5.38M+3.0%
See all 114 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/AKTS

Earnings Per Share

13fpro.ai/company/AKTS

Loading ratio trend…

AKTS insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Aktis Oncology, Inc. (AKTS): stock profile, AI score and financials

Aktis Oncology, Inc. (AKTS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. AKTS is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Aktis Oncology, Inc. reports quarterly revenue of $3.4M, net income of $-24.1M, free cash flow of $-21.8M. AKTS trades on the Nasdaq exchange and files with the SEC under CIK 2035832. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AKTS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aktis Oncology, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 2035832 →